SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress.

Summary

In SGLT2-deficient mice under diabetogenic stress, renal SAM levels increased and correlated with improved kidney function and repression of NF-κB–related genes via enhanced H3K27 trimethylation. Pharmacologic inhibition of MAT2A (reducing SAM synthesis) abolished kidney protection, positioning SAM-dependent epigenetic remodeling as a key mediator of SGLT2 inhibitor nephroprotection.

Key Findings

• Renal SAM levels increased in SGLT2-deficient mice under high-fat diabetogenic stress and associated with improved kidney function.
• NF-κB pathway gene expression was reduced with concomitant increases in H3K27 trimethylation at these loci.
• Inhibition of MAT2A (SAM synthetase) abrogated the kidney-protective phenotype, implicating SAM production as necessary.
• Injured proximal tubular cells in mice and humans showed reduced MAT2A/MAT2A expression under HFD conditions.

Clinical Implications

Suggests that kidney benefits of SGLT2 inhibitors may be monitored via epigenetic or metabolite signatures (e.g., SAM, H3K27me3 at inflammatory loci). It motivates studies to stratify responders and to explore adjunct therapies that modulate SAM/MAT2A pathways.

Limitations

• Preclinical mechanistic work; clinical corroboration of SAM/H3K27me3 biomarkers in patients on SGLT2 inhibitors is pending.
• Specificity to diet-induced metabolic stress contexts may limit generalizability to other CKD etiologies.

Future Directions

Prospective human studies to quantify renal SAM and H3K27me3 signatures with SGLT2 inhibitors; evaluate whether MAT2A/SAM modulation augments renoprotection; integrate single-cell epigenomics to map cell-type–specific effects.